Professor Zhu Jianwei's team from Shanghai Jiaotong University discovered broad-spectrum neutralizing antibodies against SARS-CoV-2

Since the first positive COVID-19 case was confirmed in late 2019, the SARS-CoV-2 virus has caused more than 400 million infections worldwide

After the outbreak of the new crown epidemic, the team of Professor Zhu Jianwei of the Engineering Research Center for Cell Engineering and Antibody Drugs of the Ministry of Education cooperated with many domestic and foreign enterprises and institutions to clone and screen the B cells of recovered patients to obtain a number of SARS-CoV-2 viruses.

The study first collected blood samples from patients who had recovered from the new crown, isolated memory B cells from them, and then cloned hundreds of IgG antibody molecules

Figure 1.

Then the research team explored the effect of some major mutation sites and major mutant strains on the activity of antibody 2G1, and found that mutation sites such as N439K, Y453F, E484K and N501Y, as well as Alpha, Beta, Gamma and Delta strains that caused concern were all affected by The activity of 2G1 did not constitute a significant effect (Fig.

Figure 2.

This study evaluated the in vivo activity of antibody 2G1 using both a transgenic mouse model and a rhesus monkey model

The structural analysis results of cryo-electron microscopy showed that the antibody 2G1 bound to the tip region of the S protein trimer through extensive hydrophobic interactions, and the binding area to the S protein was very small, avoiding most of the mutation sites.

Figure 3.

In this study, a series of valuable SARS-CoV-2 neutralizing antibodies were screened through B cell cloning technology, which has very positive significance for the treatment of new crown infection and the control of new crown epidemic

Paper link : https:// class="Article-source form-horizontal">